# Scale-invariant magnetoresistance in a cuprate superconductor

Preprint · P. Giraldo-Gallo, J. A. Galvis, Z. Stegen, K. A. Modic, F. F Balakirev, J. B. Betts, X. Lian, C. Moir, S. C. Riggs, J. Wu, A. T. Bollinger, X. He, I. Bozovic, B. J. Ramshaw, R. D. McDonald, G. S. Boebinger, A. Shekhter

- Archive id: arxiv:1705.05806
- Published: 2017-05-16
- Venue: Science 361, 479 (2018)
- DOI: https://doi.org/10.1126/science.aan3178
- arXiv: https://arxiv.org/abs/1705.05806
- Source URL: https://arxiv.org/abs/1705.05806
- PDF: https://arxiv.org/pdf/1705.05806
- Provenance: arxiv

## Abstract

The anomalous metallic state in high-temperature superconducting cuprates is masked by the onset of superconductivity near a quantum critical point. Use of high magnetic fields to suppress superconductivity has enabled a detailed study of the ground state in these systems. Yet, the direct effect of strong magnetic fields on the metallic behavior at low temperatures is poorly understood, especially near critical doping, $x=0.19$. Here we report a high-field magnetoresistance study of thin films of \\LSCO cuprates in close vicinity to critical doping, $0.161\\leq x\\leq0.190$. We find that the metallic state exposed by suppressing superconductivity is characterized by a magnetoresistance that is linear in magnetic field up to the highest measured fields of $80$T. The slope of the linear-in-field resistivity is temperature-independent at very high fields. It mirrors the magnitude and doping evolution of the linear-in-temperature resistivity that has been ascribed to Planckian dissipation near a quantum critical point. This establishes true scale-invariant conductivity as the signature of the strange metal state in the high-temperature superconducting cuprates.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.